Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-01-16Clinical Trial Update: Plasma Exchanges in Multiple Sclerosis (MS) Relapses [Phase 3]
Phase 3 clinical trial update on plasma exchanges for relapses in multiple sclerosis; study completed.
-
FDA approval · 2017-12-19FDA Approved: AUBAGIO — Supplemental Application (Genzyme Corporation)
The FDA approved a supplemental application for Aubagio (teriflunomide) by Genzyme Corporation.
-
FDA approval · 2017-12-15FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approves a supplemental application for GILENYA (fingolimod HCl) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2017-12-15FDA Approved: TECFIDERA — Supplemental Application (Biogen Inc.)
FDA approved Biogen's supplemental application for TECFIDERA (dimethyl fumarate).
-
CLINICAL_TRIALS trial_result · 2017-12-14Clinical Trial Update: A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly [Phase 2]
Phase 2 trial evaluating supplementary cholecalciferol with subcutaneous interferon beta-1a in relapsing multiple sclerosis; completed with …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-12-06Clinical Trial Update: Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study [NA]
This ClinicalTrials.gov update notes the completion of the Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness study, …
-
CLINICAL_TRIALS trial_result · 2017-12-05Clinical Trial Update: Pediatric Onset Multiple Sclerosis in Egyptians
This clinical trial update notes a completed study focusing on pediatric-onset multiple sclerosis in Egyptian participants. No specific effi…
-
FDA approval · 2017-11-28FDA Approved: BACLOFEN — Original Application (TruPharma LLC)
FDA approved the original ANDA for baclofen, a generic version produced by TruPharma LLC.
-
CLINICAL_TRIALS trial_result · 2017-11-27Clinical Trial Update: Effectiveness of Acceptance and Commitment Therapy Self-Help for Carers of People With Multiple Sclerosis [NA]
A clinical trial update evaluates the effectiveness of a self-help Acceptance and Commitment Therapy program for carers of people with multi…
-
CLINICAL_TRIALS trial_result · 2017-11-20Clinical Trial Update: Effect of Video Game Based Physical Activity Training in Persons With Multiple Sclerosis [NA]
This clinical trial investigating video game-based physical activity training in people with Multiple Sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2017-11-20Clinical Trial Update: Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects [NA]
The clinical trial evaluating task-oriented circuit training with cerebellar transcranial direct current stimulation in people with multiple…
-
CLINICAL_TRIALS trial_result · 2017-11-17Clinical Trial Update: Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis
This update reports the completion of an Optical Coherence Tomography (OCT) trial in patients with Relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: Integrative Group-based Cognitive Rehabilitation Efficacy in Multiple Sclerosis [NA]
A completed clinical trial evaluating integrative group-based cognitive rehabilitation in people with multiple sclerosis.
-
EMA approval · 2017-11-10New medicine for multiple sclerosis
EMA announces a new medicine for multiple sclerosis, indicating a new treatment option entering the European market.
-
CLINICAL_TRIALS trial_result · 2017-11-06Clinical Trial Update: Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension
A three-year extension study evaluating cognitive outcomes in multiple sclerosis patients treated with Tysabri (natalizumab) has completed.
-
CLINICAL_TRIALS trial_result · 2017-11-06Clinical Trial Update: Stress Urinary Incontinence in Women With Multiple Sclerosis
This clinical trial update notes the completion of a study on stress urinary incontinence in women with multiple sclerosis.
-
FDA approval · 2017-11-02FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for OCREVUS (ocrelizumab) from Genentech, Inc., authorizing changes to the product's labeling.
-
EMA safety_alert · 2017-10-27PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage
The EMA’s PRAC recommends additional restrictions for Zinbryta (daclizumab) due to risks of serious liver injury, including potential life-t…
-
CLINICAL_TRIALS trial_result · 2017-10-18Clinical Trial Update: BAY86-5046 (Betaseron), Non Interventional Studies
Bayer's non-interventional studies of Betaseron (interferon beta-1b) for multiple sclerosis have completed.
-
CLINICAL_TRIALS research · 2017-10-12Clinical Trial Update: Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis [Phase 2]
Endpoint calibration update for a Phase 2 study of lisinopril in relapsing-remitting multiple sclerosis. The update is associated with Trans…
-
CLINICAL_TRIALS trial_result · 2017-10-10Clinical Trial Update: Respiratory Monitoring of Intrathecal Baclofen- a Feasibility Study
This document reports the completion of a feasibility study assessing respiratory monitoring in people receiving intrathecal baclofen therap…
-
FDA approval · 2017-10-03FDA Approved: GLATIRAMER ACETATE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved the original application for glatiramer acetate (ANDA 206936) from Mylan Pharmaceuticals, a generic version of Copaxone for mul…
-
FDA approval · 2017-10-03FDA Approved: GLATIRAMER ACETATE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approves Mylan's original application (ANDA) for glatiramer acetate, a generic version of Copaxone, for the treatment of multiple sclero…
-
FDA approval · 2017-09-29FDA Approved: AMPYRA — Supplemental Application (Merz Pharmaceuticals, LLC)
FDA approved a supplemental application for AMPYRA (dalfampridine) submitted by Merz Pharmaceuticals, LLC.
-
CLINICAL_TRIALS trial_result · 2017-09-28Clinical Trial Update: Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms [Phase 2]
Phase 2 clinical trial update evaluating the safety, tolerability, and efficacy of orally administered PTL201 in multiple sclerosis patients…